- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01577095
Evaluating the Effects of Electroacupuncture and Rosiglitazone Combined Therapy
A Randomized Controlled Trial Evaluating the Effects of Electroacupuncture and Rosiglitazone Combined Therapy on Patients With Type 2 Diabetes Mellitus
Aims: To evaluate the efficacy of rosiglitazone (TZD) and electroacupuncture (EA) combined therapy on patients with type 2 diabetes mellitus (T2DM). A randomized single-blind placebo controlled clinical trial was used.
Methods: A total of 31 newly diagnostic type 2 diabetic patients, who fulfilled the eligibility criteria were recruited and received various allocated interventions. They were randomly assigned into two groups, the control group (TZD, N=15) and the experimental group (TZD + EA, N=16). Changes in their plasma free fatty acid (FFA), glucose and insulin levels together with their homeostasis model assessment (HOMA) indices were statistically assessed between before and after treatment. Hypoglycemic activity (%) was also compared between these two groups.
Expecting Results: This study will compare the hypoglycemic activity and the ability of improving insulin resistance between the TZD and TZD+EA group. Also, the lowering effect of the plasma FFA concentration will be investigated.
Studieoversigt
Status
Intervention / Behandling
Detaljeret beskrivelse
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
-
Taichung, Taiwan, 404
- Department of Integrative Chinese-Western Clinic, China Medical University Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- all included native Taiwanese patients, age from 20 to 65 years who diagnosed with type 2 diabetes mellitus within 5 years and keep the same anti-hyperglycemic agents for control diabetes before and during the period in this study
- compatible with the diagnostic criteria of diabetes mellitus according to American Diabetes Association
Exclusion Criteria:
- individuals with nephrotic syndrome (urine protein over 3.5 g/day) and edema or renal failure (serum creatinine over 115 μmol/L)
- individuals who were diagnosed of heart failure (NYHA Fc III~IV) or pacemaker implantation
- individuals with abnormal liver function (GOT and GPT level above 2 folds of normal range) or diagnosis of liver cirrhosis
- individuals with higher HbA1C level (HbA1C above 9%)
- pregnant women
- individuals who were receiving the classes of drugs thiazolidinediones already
- individuals who were receiving insulin therapy already
- individuals who were receiving other therapy during the period of study
- individuals suffering a homeostasis disorder or other systemic disease
- individuals who did not comply with the treatment during the study period
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: EA + Rosiglitazone
|
electroacupuncture and Rosiglitazone combined therapy on patient of type II DM
Andre navne:
|
Placebo komparator: Rosiglitazone
|
Rosiglitazone 8 mg single dose
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
plasma glucose
Tidsramme: Time point(s) at which outcome measure is assessed in one year
|
The primary endpoint with respect to plasma glucose level after treatment in each group of patients and compare the hypoglycemic activity between these two independent groups.
|
Time point(s) at which outcome measure is assessed in one year
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
plasma free fatty acid (FFA)
Tidsramme: Time point(s) at which outcome measure is assessed in one year.
|
This secondary endpoint will compare the percent change of plasma FFA level between these two independent groups.
|
Time point(s) at which outcome measure is assessed in one year.
|
plasma insulin
Tidsramme: Time point(s) at which outcome measure is assessed in one yease
|
This secondary endpoint will compare the plasma insulin level after treatment of each group and the change between these two independent groups.
|
Time point(s) at which outcome measure is assessed in one yease
|
Samarbejdspartnere og efterforskere
Efterforskere
- Ledende efterforsker: Shih-Liang Chang, PhD, China Medical University, China
Publikationer og nyttige links
Generelle publikationer
- Pai HC, Tzeng CY, Lee YC, Chang CH, Lin JG, Cheng JT, Chang SL. Increase in plasma glucose lowering action of rosiglitazone by electroacupuncture at bilateral Zusanli acupoints (ST.36) in rats. J Acupunct Meridian Stud. 2009 Jun;2(2):147-51. doi: 10.1016/S2005-2901(09)60047-9.
- Lin RT, Pai HC, Lee YC, Tzeng CY, Chang CH, Hung PH, Chen YI, Hsu TH, Tsai CC, Lin JG, Chang SL. Electroacupuncture and rosiglitazone combined therapy as a means of treating insulin resistance and type 2 diabetes mellitus: a randomized controlled trial. Evid Based Complement Alternat Med. 2013;2013:969824. doi: 10.1155/2013/969824. Epub 2013 Jul 29.
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- DMR94-IRB-139
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med EA + Rosiglitazone
-
Guang'anmen Hospital of China Academy of Chinese...AfsluttetStressurininkontinensKina
-
Shijiazhuang Yiling Pharmaceutical Co. LtdFirst Affiliated Hospital, Sun Yat-Sen UniversityTilmelding efter invitationAkut iskæmisk slagtilfældeKina
-
Zunyi Medical CollegeGuizhou Provincial People's Hospital; Binzhou Medical University; Union Hospital... og andre samarbejdspartnereAktiv, ikke rekrutterendeRobotic versus Thoracoscopy Versus Thoracotomy Repair for medfødt esophageal atresi (RR VS TR VS OR)Medfødt esophageal atresiKina
-
Kyunghee UniversityNational Rehabilitation Center, Seoul, Korea; Wonkwang University Gwangju...AfsluttetSlag | Skuldersmerter | Cerebralt infarkt | Hjerneblødning | Slagtilfælde, KomplikationKorea, Republikken
-
National Institutes of Health Clinical Center (CC)RekrutteringCerebral Parese | Muskeldystrofi | Spina Bifida | Ufuldstændig rygmarvsskadeForenede Stater
-
National Institutes of Health Clinical Center (CC)RekrutteringCerebral Parese | Muskeldystrofi | Spina Bifida | Ufuldstændig rygmarvsskadeForenede Stater
-
Endogena Therapeutics, IncAktiv, ikke rekrutterendeRetinitis Pigmentosa | Retinitis Pigmentosa syndromForenede Stater
-
Xijing HospitalUkendt
-
West Virginia UniversityUkendtMedfødt hjertefejlForenede Stater
-
Memorial Sloan Kettering Cancer CenterRekrutteringKemoterapi-induceret perifer neuropati | NervesmerterForenede Stater